Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Mineralys Therapeutics Inc MLYS

Healthcare Biotechnology
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MLYS)

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

GlobeNewswire 17 hours ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 2 days ago

Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

GlobeNewswire 5 days ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

GlobeNewswire October 21, 2025

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

GlobeNewswire September 30, 2025

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need  

GlobeNewswire September 5, 2025

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 4, 2025

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

GlobeNewswire September 2, 2025

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire September 2, 2025
View More News ››

Opinion & Analysis (NDAQ:MLYS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MLYS)

Buy buddy buy because it's taking off this morning.

This company is working on a big blockbuster drug program for its years
coolfooldumbguy - March 10, 2025

Using technical analysis for this stock.

This biopharmaceutical company is doing really well with its drug trials and it should keep going steadily upward from this point forward...
coolfooldumbguy - March 10, 2025

Buy buddy buy.

Otherwise you guys out there will be missing out on this stock today and it's going to be taking off to upside this morning,so good...
coolfooldumbguy - March 10, 2025
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Publicly listed in Canada (CSE: FNQ) with quoted symbols on Nasdaq (OTC: FNQQF) and the Frankfurt Stock Exchange (Frankfurt ...
View More »